Creative Medical Technology issues mid-year pipeline update

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) issued a mid-year update from CEO Timothy Warbington on July 1, 2026, outlining clinical and regulatory progress across its three core programs.

The company's lead candidate, Olastrocel (CELZ-201), is being evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease. Interim blinded 180-day data reported in January showed statistically significant improvements in disability and pain, with no serious adverse events confirmed by an independent Data Safety Monitoring Board. In June, the FDA cleared an expansion of the trial to enroll patients receiving less than 90 mg per day in morphine equivalents. That new cohort is more than 85% enrolled.

The World Health Organization approved "Olastrocel" as the International Non-Proprietary Name for the active cellular substance in CELZ-201 late last year.

In April, the company reported pilot results for Ultrasome, its cell-free regenerative therapy for knee osteoarthritis. The study reached its primary endpoint, with 93% of patients showing clinically meaningful improvements in mobility and pain, and no serious adverse events reported.

The company's biodefense program, Project PHOENIX, advanced in June into a nationwide AI-enabled virtual data collection phase targeting at least 1,000 U.S. veterans affected by toxic burn pit exposure. The program feeds data into the CELZ-Biodefense Toxic Exposure Atlas, which integrates exposure history, clinical outcomes, and multi-omics datasets. The BioDefense Inc. Burn Pit Initiative received regulatory approval to proceed nationally earlier this year.

Warbington stated the company intends to align future capital raises with defined milestones and prioritize non-dilutive funding sources such as grants and partnerships where possible.

You May Also Be Interested In

• US's Greer Says Usmca Shifting To Rolling Talks, No Renewal - Bloomberg
• Market Vectors Semiconductor ETF (SMH) 7K contracts of July 540 puts trade, share down 4.6%
• Hologic recalls BioZorb markers after reported injuries - FDA